CytomX Therapeutics, Inc. (CTMX) company profile
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
About CytomX Therapeutics
Pharmaceutical Preparations, SIC 2834
CytomX is a clinical-stage biopharmaceutical company that develops conditionally activated biologic therapies for cancer treatment. Its PROBODY platform designs biologics that stay inactive in healthy tissue and activate in tumor microenvironments through protease cleavage. The pipeline includes antibody-drug conjugates, T-cell engagers, cytokines, and messenger RNA. Its lead investigational programs include varsetatug masetecan, an antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, a masked interferon alpha-2b cytokine for advanced melanoma. The company collaborates with pharmaceutical partners, including Amgen, Bristol Myers Squibb, Astellas, Regeneron, and Moderna, and targets oncology patient populations.
Regarding operational scale, more than 500 patients have received treatment with the company's candidate therapies across multiple clinical trials. In addition, CytomX holds a patent portfolio containing at least 245 granted patents and at least 300 pending patent applications as of January 2026. The provided text does not state the location of the company's headquarters, nor does it disclose geographic details regarding its corporate offices or operational facilities.
Summary of the business section of CytomX Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CytomX Therapeutics, Inc.
- Founded
- 2008
- Headquarters
- South San Francisco, CA
- Address
- 151 Oyster Point Blvd., Suite 400 94080
- Phone
- (650) 515-3185
- Website
- cytomx.com
- Employees
- 69, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- CTMX
- Exchange
- Nasdaq
- IPO date
- Oct 8, 2015
- Shares outstanding
- 218M, Jul 31, 2026
- Public float
- $372.30M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1501989
- CUSIP
- 23284F105
- ISIN
- US23284F1057
- FIGI
- BBG001J472L3
- Share class FIGI
- BBG001V0GS49
- LEI
- 5493004VW2FW0QLL3345
- EIN
- 27-3521219
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sean A. McCarthy | CEO, Director | 2,263,891 |
| Alejandra Carvajal | Chief Legal Officer | 100,000 |
| Christopher Ogden | Chief Financial Officer | 295,324 |
| Marcia Belvin | SVP, Chief Scientific Officer | 300,760 |
| Yu-Waye Chu | Chief Medical Officer | 189,446 |
| Rachael Lester | Chief Business Officer | 20,000 |
| Lloyd A. Rowland | General Counsel | 120,594 |
| Charles S. Fuchs | Director | – |
| Halley E. Gilbert | Director | – |
| Matthew P. Young | Director | – |
| Alan Ashworth | Director | – |
| James R. Meyers | Director | – |
| Elaine V. Jones | Director | 5,142 |
| Zhen Su | Director | – |
| Mani Mohindru | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.74M | $10.64M | $1.89M | $266 | – |
| FY2024 | $1.75M | $1.06M | $861.32K | $64 | – |
| FY2023 | $2.61M | $519.37K | $1.13M | $97 | – |
| FY2022 | $3.01M | $671.92K | $1.38M | $37 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Sean A. McCarthy, D. Phil. Chief Executive Officer and Chairman of the Board of Directors | $675.29K | – | $1.15M | $2.16M | $749.57K | $5.00K | $4.74M | +170% |
| Chris Ogden Senior Vice President, and Chief Financial Officer | $478.65K | – | $224.93K | $446.37K | $387.68K | $5.00K | $1.54M | +69% |
| Rachael Lester Senior Vice President and Chief Business Officer | $77.02K | $120.00K | – | $1.99M | $44.50K | – | $2.23M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 8, 2015
- Offer price
- $12.00
- Securities offered
- 6,666,667
- Gross proceeds
- $80.00M
- Exchange
- Nasdaq
- First trading day
- Oct 8, 2015
- First-day close
- $12.90+7.5%
- Lock-up ends (est.)
- Apr 5, 2016
“PER SHARE TOTAL Public Offering Price $12.00 $80,000,004 Underwriting Discounts and Commissions* $0.84 $5,600,000 Proceeds to us before expenses $11.16 $74,400,004 * We refer you to “Underwriting” beginning on page 157 for additional information regarding underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 69 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 26, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 17, 2017 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Oct 8, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 6, 2015 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?